Introduction
============

In 2011, esophageal carcinoma was the fifth and eighth most common cause of death worldwide in men and women, respectively.[@b1-ott-8-573] Esophageal carcinoma has a very poor survival rate, with the 5-year survival rate in developed countries ranging from 10% to 16%.[@b2-ott-8-573] On a global scale, the incidence of esophageal carcinoma is especially high in People's Republic of China, although it varies widely between provinces. Esophageal squamous cell carcinoma (ESCC) is the major histological type in Chinese populations, with a mortality rate that ranks fourth among all the cancer-related mortalities, resulting in 150,000 deaths annually.[@b3-ott-8-573]

The etiology of ESCC has not been fully elucidated, although the involvement of human papillomavirus (HPV) infection in esophageal carcinoma was first suggested in 1982.[@b4-ott-8-573] In Shaan Xi, an ESCC high-incidence region in the northwest of People's Republic of China, high-risk HPV16/18 infection has been associated with the development of ESCC.[@b5-ott-8-573] It was postulated that high-risk HPV was involved in the very early stage of the classical dysplasia-carcinoma sequence of ESCC because of the presence of HPV DNA in normal esophageal epithelium and cancer precursor lesions.[@b6-ott-8-573]

High-risk HPV16 E6 protein is a major oncoprotein that interferes with cell cycle regulation and enhances tumorigenesis by binding to the p53 tumor suppressor, leading to rapid p53 degradation via the ubiquitin--proteasome system.[@b7-ott-8-573] Therefore, the detection of HPV16 E6 oncoprotein in tissues might suggest the etiological involvement of HPV16 in ESCC.

In HPV-positive head and neck squamous cell carcinoma, the presence of a small subpopulation of cancer stem cells (CSCs) with the capacity for self-renewal has been suggested as underlying treatment-resistance.[@b8-ott-8-573] CSCs are regarded as tumor cells that maintain tumor growth and cell differentiation. Consequently, CSCs represent novel therapeutic targets because of their concentrated representation of pathological cancer characteristics. In normal human esophageal epithelial cells, a candidate stem/progenitor cell fraction was identified in vitro by the expression of the low-affinity p75 neurotrophin receptor (p75NTR). These cells have a slow cycling rate, a relatively immature phenotype, and are capable of repopulating all known epithelial cell subtypes. Therefore, expression levels of p75NTR could be considered as a candidate biomarker of CSCs in ESCC tumors.[@b9-ott-8-573],[@b10-ott-8-573]

Many reports have confirmed that abnormal activation of the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway plays a critical role in tumorigenesis of cancers including ESCC. Recently, it has been suggested that activation of the PI3K/Akt pathway is essential for the maintenance and viability of CSCs in breast cancer, prostate cancer, and brain tumors.[@b11-ott-8-573],[@b12-ott-8-573] In addition, inhibiting the PI3K/Akt pathway might result in differentiation of CSCs.[@b13-ott-8-573]

In the present study, the expression of HPV16 E6, p75NTR, and the PI3K in postoperative tissues resected from patients with ESCC or benign esophageal tumor or normal esophageal epithelial tissues were evaluated using immunohistochemical staining (IHC). Correlation analysis of those potential markers with clinical features and prognostic 3-year, 5-year overall survival (OS) and progression-free survival (PFS) rates were performed.

Materials and methods
=====================

Patients and surgical specimens
-------------------------------

Surgical specimens, including 54 controls (benign or inflammation hyperplasia) and 103 cases (ESCC) were retrieved from patients who underwent an esophagectomy at The First Affiliated Hospital of Xi'an Jiao Tong University between September 2008 and December 2009. Patients who had received neoadjuvant treatment, who had positive resection margins (R1) according to the College of American Pathologists criteria, who had distant metastases, or those who did not reside in Shaan Xi Province were excluded from the study. The study was approved by the Ethics Committee of The First Affiliated Hospital of Xi'an Jiao Tong University, and written informed consent was obtained from all patients.

Immunohistochemical staining
----------------------------

Tissues were fixed in 10% buffered formalin and embedded in paraffin then processed by standard methods. IHC was performed using an Envision system according to manufacturer's instructions. Primary antibodies included mouse monoclonal anti-HPV16 E6 (\#C1P5; Abcam, Cambridge, UK), rabbit polyclonal anti-human p75NTR (MAB367; R&D Systems, Inc., Minneapolis, MN, USA), and rabbit polyclonal anti-human PI3K (\#4249; Cell Signaling Technology, Danvers, MA, USA). Normal epithelium was used as an internal positive control for each specimen. Negative controls were obtained by omitting the primary antibody. The proportion of positively stained cells and all tumor cells were counted over five random fields in each section, and the percentage of positively stained cells in each section was calculated. Each sample was categorized according to the area of stained cells and the intensity of staining, and the sum of the two constituted the final score. For area scoring: 0 indicated no positive staining; 1, ≤10% of tissue stained; 2, 11%--50% of tissue stained; 3, 51%--75% of tissue stained; and 4, \>.75% of tissue stained. For intensity scoring: 0 was no staining; 1, weak staining; 2, moderate staining; and 3, strong staining. Specimens were considered positive when the score was ≥4. All slides were evaluated independently by two pathologists in a blinded fashion. For any discrepancies, a consensus was made by careful discussion between the pathologists.

Follow-up visit
---------------

All 103 patients with ESCC attended a clinic-based follow-up every 6 months for 5 years or until death. Follow-up included general health, physical and imaging examinations, biochemical testing, and a record of survival status.

Statistical analyses
--------------------

The association between the protein expression levels and clinical features were evaluated using the *χ*^2^ test. Pearson's correlation coefficients were calculated to analyze any correlations between the expression levels of the three proteins. The Mann--Whitney *U*-test was performed to compute the differences in p75NTR and PI3K expression between HPV16 E6-positive and HPV16 E6-negative cases. Kaplan--Meier analysis (log rank test) was used to compare the OS, which was defined as the time from the date of surgery to death, and PFS, which was defined as the time from the date of surgery to the first documented relapse of patients, between the patient groups. Cox regression analysis and the Cox proportional hazards model were applied to determine the hazard ratio (HR) of variables on 5-year OS and PFS in univariate and multivariate analysis. A two-sided *P*-value of \<0.05 was considered statistically significant. All analyses were performed using SPSS version 19.0 for Windows.

Results
=======

Expression of HPV16 E6, p75NTR, and PI3K in ESCC and control tissues
--------------------------------------------------------------------

The baseline characteristics of patients with ESCC and control patients are shown in [Table 1](#t1-ott-8-573){ref-type="table"}. Of the 103 resected ESCC specimens, HPV16 E6, p75NTR, and PI3K expression was positive in 63.1%, 61.2%, and 72.8%, respectively ([Figure 1](#f1-ott-8-573){ref-type="fig"}). Of the 54 control specimens, HPV16 E6, p75NTR, and PI3K expression was positive in 22.2%, 20.4%, and 9.3%, respectively. The expression of the three proteins was significantly higher in patients with ESCC compared with controls (*P*\<0.05, [Table 1](#t1-ott-8-573){ref-type="table"}).

Correlations between protein expression levels and clinical features in patients with ESCC and correlations between the expression of HPV16 E6, p75NTR, and PI3K
----------------------------------------------------------------------------------------------------------------------------------------------------------------

Correlations between expression levels of HPV16 E6, p75NTR, and PI3K with clinical features such as patient age, sex, and histology are shown in [Table 2](#t2-ott-8-573){ref-type="table"}. HPV16 E6 expression was higher in men compared with women (*P*\<0.05). p75NTR expression was higher in those aged \>56 years (*P*\<0.05). Higher PI3K expression was associated with a more advanced histopathological grade (*P*\<0.05). The expression of p75NTR and PI3K was significantly different between different tumor node metastasis (TNM) stage groups of patients with ESCC (*P*\<0.05), while there was no significant difference in HPV16 E6 expression between different TNM stage groups in control patients. Meanwhile, the expression of the three proteins was not correlated with smoking status, infiltration depth, lymph nodes status, or the general classification of patients with ESCC (*P*\>0.05).

As shown in [Table 2](#t2-ott-8-573){ref-type="table"}, according to the Pearson's correlations analysis, there was a positive correlation between HPV16 E6 and p75NTR expression level in ESCC tumors (*r*=0.547, *P*\<0.001). There was also a positive correlation between p75NTR and PI3K expression in ESCC tumors (*r*=0.364, *P*\<0.001). However, there was no significant correlation between PI3K and HPV16 E6 expression (*r*=0.166, *P*\>0.05).

Survival analysis and prognostic value of HPV16 E6, p75NTR, and PI3K expression in patients with ESCC
-----------------------------------------------------------------------------------------------------

The follow-up rate, which was defined as the number of patients without loss to follow-up as a proportion of the total number of patients recruited, was 97.1% (100/103). The follow-up ended on September 25, 2014, with a mean follow-up of 32.64 months (range 7--67 months), and the estimated 5-year OS was 11% (11/100). According to the Kaplan--Meier analysis, age \>56 years, male sex, an advanced TNM stage, a general classification of medullary type ESCC, and no postoperative adjunctive treatment were significantly associated with poor OS and PFS (*P*\<0.05, [Table 3](#t3-ott-8-573){ref-type="table"}). Smoking status, tumor differentiation, and lymph node status were not correlated with the OS or PFS (*P*\>0.05, [Table 3](#t3-ott-8-573){ref-type="table"}). However, the infiltration depth was correlated with OS but not with PFS (*P*\<0.05, *P*\>0.05, respectively, [Table 3](#t3-ott-8-573){ref-type="table"}).

Furthermore, as shown in [Table 4](#t4-ott-8-573){ref-type="table"} and [Figure 2](#f2-ott-8-573){ref-type="fig"}, multivariate analysis revealed that HPV16 E6-positive or PI3K-positive patients had significantly worse 5-year OS compared with HPV16 E6-negative or PI3K-negative patients (HR =1.874, *P*=0.021; HR =1.961, *P*=0.011, respectively). These patients also had a significantly worse PFS (HR =1.740, *P*=0.04; HR =2.077, *P*=0.006, respectively). The TNM stage was also an independent factor of poor prognosis for 5-year OS (HR =1.506, *P*=0.03), but not the PFS (HR =1.410, *P*\>0.05). No significant correlations were found between the expression of p75NTR and 5-year OS or PFS (*P*\>0.05) or postsurgical treatment and 5-year OS or PFS (*P*\>0.05).

The 3-year OS was also taken into consideration, as shown in [Table 4](#t4-ott-8-573){ref-type="table"} and [Figure 2](#f2-ott-8-573){ref-type="fig"}; HPV16 E6-positive patients with ESCC had significantly worse 3-year OS compared with HPV16 E6-negative patients with ESCC (HR =2.118, *P*\<0.05). In addition, PI3K-positive patients with ESCC had significantly worse 3-year OS compared with PI3K-negative patients with ESCC (HR =1.896, *P*\<0.05). There were no significant differences in 3-year OS based on p75NTR expression (HR =1.247, *P*\>0.05).

Discussion
==========

The prevalence of HPV infection in esophageal premalignant lesions or carcinoma varies (0%--88%) in different populations and from study to study.[@b14-ott-8-573] Variations in sampling methods, demographic and ethnic factors, anatomic sites, and methods used for viral detection have all been suggested as potential causes of these discrepancies. IHC measures of HPV activity in cervical and head and neck cancer were used to analyze the expression of the surrogate marker p16^INK4a^.[@b15-ott-8-573] Consequently, detection of the HPV16 oncoprotein E6 was utilized as a surrogate marker in the current study to detect HPV infection.

Here, the incidence of HPV16 E6-positivity was significantly higher in patients with ESCC compared with controls, suggesting that, in Shaan Xi Province, the prevalence of HPV16 among patients with ESCC is considerably high, and that high-risk HPV infection may be a carcinogenic factor underlying the etiology of ESCC. These results are concordant with those of other studies. For example, a study in a population in Anyang, People's Republic of China revealed that HPV16 E7 antibody was detected at a significantly higher level in patients with ESCC, compared with control patients.[@b16-ott-8-573] Moreover, HPV DNA detection was as high as 65% in Gansu, which has one of the highest incidences of ESCC in People's Republic of China.[@b17-ott-8-573]

In patients with HPV16/18-positive cervical cancer, E6/E7 oncogene expression was independently associated with a poor prognosis.[@b18-ott-8-573] In addition, the 5-year survival rate of HPV DNA-positive patients with vulvar squamous cell carcinoma was lower than that of HPV-negative patients.[@b19-ott-8-573] However, whether or not HPV16 infection status could serve as an independent prognostic marker in patients with ESCC has been debatable. A pilot study detected HPV16 in patients with ESCC alone, but HPV16 infection status did not significantly affect survival, although the authors suggested that the limited sample size might have contributed to the lack of effect on survival. However, in patients with ESCC, compared with HPV-negative patients, HPV-positive patients who received preoperative neoadjuvant chemotherapy or radiotherapy had improved treatment responses and prognosis.[@b20-ott-8-573] Here, in patients with ESCC, the 3- and 5-year OS and PFS rates of HPV16-negative patients were significantly better than those of HPV16-positive patients, inferring that HPV16 infection may be an unfavorable prognostic factor in patients with ESCC.

Expression of the high-risk HPV16 E6/E7 oncogene can lead to malignant transformation in various cell lines, and a recent study indicated that stem cells might participate in this process.[@b21-ott-8-573] Stem cells are enriched in basal cells of the normal esophageal epithelium. The α6β1 and α6β4 integrins are not only biomarkers of normal esophageal epithelial stem and progenitor cells, but they also mediate the invasion of HPV16 E6/E7 oncogene into cells.[@b22-ott-8-573] This suggests that the HPV16 E6/E7 oncogene might possibly target the stem or progenitor cells of normal esophageal epithelium to induce carcinogenesis, although further studies are needed to uncover the mechanisms underlying the carcinogenic action of the HPV16 E6/E7 oncogene in these cells.

As a member of tumor necrosis factor receptor family, p75NTR is expressed in the progenitor cells of human esophageal keratinocytes and is a marker of esophageal CSCs.[@b23-ott-8-573],[@b24-ott-8-573] In a previous study, we demonstrated that the proportion of p75NTR-positive cells increased dramatically in CSC-like radiation-resistant Eca109R-50Gy cells, which was achieved in response to 50 Gy irradiation.[@b25-ott-8-573],[@b26-ott-8-573] In the present study, p75NTR expression was significantly higher in patients with ESCC compared with controls, and the expression tended to increase with advancing tumor stage. There was also a significant positive correlation between the expression of HPV16 E6 and p75NTR, suggesting that both HPV16 infection and CSC activation may participate in ESCC progression although their potential relationship requires further investigation. However, the p75NTR expression level was not correlated with the clinical prognosis when known prognostic variables such as the TNM stage and treatment after surgery were excluded. To confirm the role of p75NTR as a positive prognostic marker in patients with ESCC, future prospective studies enrolling more patients are needed.

Activation of the PI3K/Akt signaling pathway has been implicated in human cancers including esophageal cancer. LY294002, a specific PI3K inhibitor, causes prominent cell differentiation in human embryonic stem cells.[@b27-ott-8-573] In radioresistant ESCC cells that have CSC-like properties, Akt mRNA and protein levels increased in response to irradiation, suggesting that the PI3K/Akt pathway was activated.[@b25-ott-8-573],[@b26-ott-8-573] The PI3K/Akt pathway was also important in maintaining pluripotency of mouse embryonic stem cells.[@b28-ott-8-573] Gupta et al[@b29-ott-8-573] found that the radiosensitivities of HPV-positive human head and neck squamous cell carcinoma UPCI-SCC90 and UMSCC47 cell lines were higher than that of the HPV-negative cell line SQ20B because of PI3K/Akt pathway activation. In xenografted mice bearing human gliomas, inhibition of Akt activity in CSCs resulted in sensitization of cells to treatment and promoted survival.[@b11-ott-8-573],[@b12-ott-8-573],[@b30-ott-8-573]

In concordance with previous research, PI3K expression was significantly higher in patients with ESCC compared with controls. The higher PI3K expression level was correlated with an advanced TNM stage and a poor prognosis, but there was no significant correlation between the expression of PI3K and HPV16 E6. This indicates that invasion of the HPV16 oncogene into esophageal cells and the carcinogenic process may not involve PI3K/Akt pathway activation. Further evaluation of the molecular mechanisms underlying the interaction of HPV16 E6 and PI3K/Akt signaling is required.

Conclusion
==========

High-risk HPV infection, especially HPV16, has a high prevalence, and it might play an important role in the etiology of ESCC. HPV16 infection or high PI3K expression in patients with ESCC were independently associated with poor OS and PFS, whereas p75NTR expression was not correlated with clinical prognosis.
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![The expression of HPV16 E6, p75NTR, and PI3K in ESCC tissues detected by immunohistochemical staining.\
**Notes:** HPV16 E6 protein (**A**) is expressed mainly in the nucleus and cytoplasm of esophageal squamous cell carcinoma (ESCC) patients and controls; p75NTR (**B**) and PI3K (**C**) proteins are expressed mainly in the cytoplasm and membrane of ESCCs and controls.\
**Abbreviations:** HPV16, human papillomavirus 16; PI3K, phosphatidylinositol 3-kinase; p75NTR, low-affinity p75 neurotrophin receptor.](ott-8-573Fig1){#f1-ott-8-573}

![Survival curves of 3-year OS, OS, and PFS of ESCC patients according to HPV16, p75NTR, and PI3K expression.\
**Notes:** Kaplan--Meier estimates of survival among esophageal squamous cell carcinoma (ESCC) patients, according to the tumor human papillomavirus 16 (HPV16) status or p75 neurotrophin receptor (p75NTR)-expression status or phosphatidylinositol 3-kinase (PI3K)-expression status; For the 5-year overall survival (OS) rate (**A**) and progression-free survival (PFS) rate (**D**), HPV16 positive is significantly associated with poor prognosis (*P*=0.021, *P*=0.04, respectively); For the 5-year OS rate (**B**) and PFS rate (**E**), there is no relationship between p75NTR expression and prognosis (*P*=0.312, *P*=0.368, respectively); For the 5-year OS rate (**C**) and PFS rate (**F**), PI3K positive is significantly associated with poor prognosis (*P*=0.011, *P*=0.006, respectively); Consistently, for the 3-year OS rate, HPV16 and PI3K positive (**G**, **H**, respectively) are significantly correlated with poor prognosis (*P*=0.005, *P*=0.025, respectively) while there is still no association between p75NTR and prognosis (**I**, *P*=0.408).](ott-8-573Fig2){#f2-ott-8-573}

###### 

Baseline characteristics and the expression of HPV16 E6, p75NTR, and PI3K in ESCC patients and controls

  -----------------------------------------------------------------------------------------
  Characteristics                                            ESCC patients\   Controls\
                                                             N=103            N=54
  ---------------------------------------------------------- ---------------- -------------
  Age                                                                         

   Median (range)                                            56 (38--74)      48 (22--76)

  Sex                                                                         

   Male                                                      84               30

   Female                                                    19               24

  Smoking status[\*](#tfn1-ott-8-573){ref-type="table-fn"}                    

   Yes                                                       71               26

   No                                                        32               28

  Tumor differentiation                                                       

   G1                                                        7                NE

   G2                                                        78               NE

   G3                                                        18               NE

  Infiltration depth                                                          

   Submucosa                                                 10               NE

   Superficial myoinvasion                                   11               NE

   Deep myoinvasion                                          14               NE

   Full thickness                                            68               NE

  Lymph node status                                                           

   Negative                                                  51               NE

   Positive                                                  52               NE

  General classification                                                      

   Ulcerative type                                           45               NE

   Medullary type                                            42               NE

   Fungating type                                            15               NE

   Constrictive type                                         1                NE

  TNM staging                                                                 

   I                                                         7                NE

   II                                                        58               NE

   III                                                       35               NE

   IV                                                        3                NE

  HPV16                                                                       

   Negative                                                  38               42

   Positive                                                  65               12

   *P*                                                       \<0.001          

  p75NTR                                                                      

   Negative                                                  40               43

   Positive                                                  63               11

   *P*                                                       \<0.001          

  PI3K                                                                        

   Negative                                                  28               49

   Positive                                                  75               5

   *P*                                                       \<0.001          
  -----------------------------------------------------------------------------------------

**Notes:**

The equivalent of smoking one pack of cigarettes per day for 1 year was defined as smoking status positive.

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; HPV16, human pa pillomavirus 16; PI3K, phosphatidylinositol 3-kinase; p75NTR, low-affinity p75 neurotrophin receptor; NE, not estimable; TNM, tumor node metastasis.

###### 

Correlations between the expression of HPV16 E6, p75NTR, PI3K, and clinical features in ESCC patients

                             HPV16   p75NTR   PI3K                                                 
  -------------------------- ------- -------- ----------------------- ---- ----------------------- ----
  Median age                                                                                       
   ≤56 years                 18      38       22                      34   21                      35
   \>56 years                20      27       18                      29   7                       40
   *P*                       0.275            0.918                        0.010                   
  Sex                                                                                              
   Male                      26      58       31                      53   23                      61
   Female                    12      7        9                       10   5                       14
   *P*                       0.009            0.398                        0.925                   
  Smoking status                                                                                   
   Yes                       24      47       25                      46   20                      51
   No                        14      18       15                      17   8                       24
   *P*                       0.333            0.261                        0.738                   
  Tumor differentiation                                                                            
   G1                        0       7        1                       6    1                       7
   G2                        29      49       37                      41   23                      55
   G3                        9       9        2                       16   5                       13
   *P*                       0.066            0.007                        0.243                   
  Infiltration depth                                                                               
   Submucosa                 4       6        2                       8    4                       6
   Superficial myoinvasion   3       8        3                       8    0                       11
   Deep myoinvasion          7       7        5                       9    5                       9
   Full thickness            24      44       30                      38   19                      49
   *P*                       0.662            0.396                        0.140                   
  Lymph node status                                                                                
   Negative                  18      33       18                      33   11                      40
   Positive                  20      32       22                      30   17                      35
   *P*                       0.739            0.465                        0.205                   
  TNM staging                                                                                      
   I                         2       5        2                       5    4                       3
   II                        22      36       16                      42   7                       51
   III                       14      21       19                      16   17                      18
   IV                        0       3        3                       0    0                       3
   *P*                       0.545            0.009                        0.000                   
  General classification                                                                           
   Ulcerative type           17      28       20                      25   17                      28
   Medullary type            17      25       18                      24   9                       33
   Constrictive type         0       1        0                       1    1                       0
   Fungating type            4       11       2                       13   2                       13
   *P*                       0.634            0.084                        0.097                   
  HPV16                                                                                            
   Negative                  --      --       28                      10   14                      24
   Positive                  --      --       12                      53   14                      51
   *r* and *P*                                *r*=0.547, *P*\<0.001        *r*=0.364, *P*\<0.001   
  p75NTR                                                                                           
   Negative                  --      --       --                      --   19                      21
   Positive                  --      --       --                      --   9                       54
   *r* and *P*                                                             *r*=0.166, *P*\>0.05    

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; HPV16, human papillomavirus 16; PI3K, phosphatidylinositol 3-kinase; p75NTR, low-affinity p75 neurotrophin receptor; TNM, tumor node metastasis.

###### 

Kaplan--Meier analysis of clinical features in ESCC patients

                                           Median OS (months)   *P*     Median PFS (months)   *P*
  ---------------------------------------- -------------------- ------- --------------------- -------
  Age                                                                                         
   ≤56 years                               31                           31                    
   \>56 years                              23                   0.023   18                    0.017
  Sex                                                                                         
   Male                                    21                           18                    
   Female                                  51                   0.000   48                    0.001
  Smoking status                                                                              
   Yes                                     23                           19                    
   No                                      36                   0.263   30                    0.294
  Tumor differentiation                                                                       
   G1                                      22                           13                    
   G2                                      31                           28                    
   G3                                      18                   0.369   18                    0.289
  Infiltration depth                                                                          
   Submucosa                               31                           31                    
   Superficial myoinvasion                 26                           25                    
   Deep myoinvasion                        48                           41                    
   Full thickness                          20                   0.044   18                    0.063
  Lymph node status                                                                           
   Negative                                37                           30                    
   Positive                                18                   0.316   18                    0.532
  General classification                                                                      
   Ulcerative type                         31                           30                    
   Medullary type                          19                           18                    
   Fungating type                          48                   0.009   31                    0.008
  Treatment                                                                                   
   Surgery alone                           18                           18                    
   Surgery + chemotherapy                  36                           31                    
   Surgery + radiotherapy                  37                           36                    
   Surgery + chemotherapy + radiotherapy   18                   0.007   18                    0.014
  TNM staging                                                                                 
   I                                       51                           51                    
   II                                      31                           28                    
   III                                     18                           18                    
   IV                                      14                   0.003   14                    0.001

**Abbreviations:** ESCC, esophageal squamous cell carcinoma; OS, overall survival; PFS, progression-free survival; TNM, tumor node metastasis.

###### 

Multivariate COX analysis for 3-year OS, 5-year OS, and PFS in ESCC patients

                5-year OS      PFS     3-year OS                                                          
  ------------- -------------- ------- ----------- -------------- ------- ------- --------------- ------- -------
  TNM staging   1.04--2.180    1.506   0.030       0.983--2.023   1.410   0.062   --              --      --
  Treatment     0.593--1.129   0.818   0.223       0.613--1.147   0.838   0.271   --              --      --
  HPV16         1.098--3.197   1.874   0.021       1.025--2.954   1.740   0.040   1.255--3.574    2.118   0.005
  p75NTR        0.441--1.299   0.757   0.312       0.455--1.338   0.780   0.368   0.7388--2.105   1.247   0.408
  PI3K          1.166--3.299   1.961   0.011       1.240--3.479   2.077   0.006   1.083--3.318    1.896   0.025

**Abbreviations:** CI, confidence interval; ESCC, esophageal squamous cell carcinoma; HPV16, human papillomavirus 16; HR, hazard ratio; OS, overall survival; PI3K, phosphatidylinositol 3-kinase; p75NTR, low-affinity p75 neurotrophin receptor; PFS, progression-free survival; TNM, tumor node metastasis.
